Abstract
Several transplant programs have recently added cyclophosphamide (CyP) to their immune suppression protocols in an attempt to reduce intestinal graft rejection rates. The present study was undertaken to confirm the benefits of this drug in a murine small bowel transplant model. A short course of monotherapy with CyP 20 mg/kg per dose resulted in a mean survival time (MST) of 17.5 ± 3.6 days, compared with a MST of 7.5 ± 0.7 days in the untreated controls (P < 0.01). Cyclosporin A (CsA) 30 mg/kg per day produced comparable survival rates when used as monotherapy (MST: 14.2 ± 1.3 days) or in combination with CyP 20 mg/kg per dose (MST: 21.3 ± 5.1 days). Treatment with high dose CyP (40 mg/kg per dose) completely prevented graft loss in 8 of 10 animals (MST: 72.5 ± 5.3 days, P < 0.01). However, adding CsA abrogated the induction of long-term survival achieved by CyP alone (MST: 23 ± 0.4 days). These data have important implications for the use of CyP in clinical transplantation.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 14 April 2000 Revised: 11 January 2001 Accepted: 9 May 2001
About this article
Cite this article
Kellersmann, R., Zhong, R., Garcia, B. et al. A short course of high-dose cyclophosphamide induces long-term survival of intestinal allografts in mice. Transpl Int 14, 261–265 (2001). https://doi.org/10.1007/s001470100328
Published:
Issue Date:
DOI: https://doi.org/10.1007/s001470100328